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The significance of residual lung metastasis from malignant gestational trophoblastic neoplasm (GTN) after the completion of
chemotherapy is unknown. We currently do not advocate resection of these masses. Here, we investigate the outcome of these
patients. Patients with residual lung abnormalities after the completion of treatment for GTN were compared to those who had a
complete radiological resolution of the disease. None of the residual masses post-treatment were surgically removed. In all, 76
patients were identified. Overall 53 (70%) patients had no radiological abnormality on CXR or CT after completion of treatment.
Eight (11%) patients had residual disease on CXR alone 15 patients had residual disease on CT (19%). During follow-up, two patients
(2.6%) relapsed. One of these had had a complete radiological response post-treatment whereas the other had residual disease on
CT. Patients with residual lung lesions after completing treatment for GTN do not appear to have an increased chance of relapse
compared to those with no residual abnormality. We continue to recommend that these patients do not require pulmonary surgery
for these lesions.
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Gestational trophoblastic neoplasia (GTN) encompasses a spec-
trum of disorders from the premalignant conditions of complete
and partial hydatidiform moles (CHM or PHM) to the malignant
disorders of invasive mole, choriocarcinoma, and placental site
trophoblastic tumour (PSTT). About 16% of CHM and 0.5% of
PHM transform into any of the malignant forms of GTN.
Choriocarcinoma and PSTT can also develop after any type of
pregnancy, including miscarriages and term deliveries (Seckl et al,
2000; Palmieri et al, 2005). Malignant GTN is usually diagnosed
by a plateaued or rising human chorionic gonadotrophin (hCG)
level some weeks following uterine molar evacuation. Histological
confirmation is rarely performed because of the risk of life-
threatening haemorrhage.
Malignant GTN can metastasis, most commonly to the lungs
(Kumar et al, 1988). The vast majority of these patients are cured
with chemotherapy despite the presence of metastatic disease,
although those with liver and/or brain metastases have a poorer
prognosis (Bower et al, 1997; Newlands et al, 2000). On completion
of chemotherapy, most metastatic lesions will be completely
resolved. However, in some patients, residual lesions persist
usually in the lungs. The underlying concern is that such lesions
may still harbour nests of active cancer, so should these lung
lesions be removed?
For nongestational choriocarcinomas, which despite being
pathologically similar are genetically and clinically distinct from
GTN, the answer is yes. This is because residual masses may
contain active cancer regardless of normal tumour markers
(Thompson and Goldstein, 1969; Gels et al, 1997; Hartmann
et al, 1997a,b). However, for GTN, the situation is less clear as the
disease is more chemosensitive and has an even lower relapse rate
than that of nongestational choriocarcinomas arising from ovary
(Sarwar et al, 2004). Therefore, our centre has historically observed
residual GTN masses postchemotherapy with the exception of
those in the brain, the latter being a site where chemotherapy
might be less effective because of the blood–brain barrier
(Newlands et al, 2002).
So is it safe to avoid resection of residual GTN lesions in the
chest? Here, we attempt to address this issue by comparing the
outcome for patients with or without residual radiological
abnormalities in the chest, following chemotherapy for GTN.
PATIENTS AND METHODS
The Charing Cross GTN database was screened to identify all
women diagnosed between 1995 and 2004, with GTN and lung
metastasis as the only site of metastasis. Patients with known
metastases elsewhere including the liver and brain were excluded
as these sites are associated with a worse prognosis and could
confound the results. Only patients whose hCG levels had
normalised for 6 weeks during chemotherapy and remained
normal for 6 weeks following completion of chemotherapy, and
were therefore biochemically thought to be cured, were included
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sin the subsequent analysis. Clinical, biochemical and radiological
details (either computer tomography (CT) or chest X-ray (CXR),
or both) at presentation and on completion of chemotherapy were
recorded. At presentation for chemotherapy, patients were staged
according to nationally and internationally accepted criteria for
GTN, stratified into low- or high-risk groups, and treated
accordingly (Bagshawe, 1976; Kohorn, 2001; McNeish et al,
2002). Individuals with low-risk disease were treated with
subcutaneous methotrexate and folinic acid, whereas those with
high-risk disease were given weekly combination chemotherapy,
comprising of etoposide, methotrexate, and actinomycin altern-
ating with cyclophospohmide and vincristine (EMA/CO). Resis-
tance to methotrexate occurred in a minority of patients while on
treatment, and therapy was changed to either actinomycin or
EMA/CO depending on the level of hCG at the time of resistance as
previously described (McNeish et al, 2002). During follow-up,
disease-free patients outcome was recorded and plotted according
to the Kaplan–Meier method. This study was approved by our
local institutional review board.
RESULTS
Between 1995 and 2004, 681 patients received chemotherapy for
malignant GTN. At presentation, 76 patients (11%) had lung
metastases as the only overt metastatic site, and following
chemotherapy, all had normal serum hCG levels and were thought
to be cured. Nevertheless, 23/76 (30%) had persistent pulmonary
radiological lesions. No pulmonary lesions were identified in the
remaining 53 patients on either CXR and/or CT scanning after
treatment.
The characteristics of patients with and without radiological
abnormality, at the end of treatment are shown in Table 1. It is
noteworthy that the median age at presentation, initial hCG,
duration of treatment and proportion of patients receiving
combination treatment, in the two groups are not significantly
different (P40.05 for each). Table 2 compares and contrasts
specific factors including number and size of lung metastasis at
presentation, the type of radiological investigation used at the end
of treatment (CXR or CT), and the type of GTN with the risk of
having persistent pulmonary lesions. Of these factors, only patients
with lung lesions 42cm at the start of the treatment or those who
were imaged by CT scan (rather than CXR) were found to have a
significantly increased chance of residual disease on completion of
treatment (Table 2). In contrast, neither the number of metastases
at presentation nor the presence of confirmed choriocarcinoma
altered the risk of detecting residual lesions.
Overall, two patients relapsed after chemotherapy. Both patients
had nonmolar choriocarcinoma that followed term delivery. One
patient had multiple metastasis at the start of the treatment, the
largest of which was 5cm, and an hCG of 102000IUl
 1. She was
treated with combination chemotherapy for 21 weeks. At the end
of the treatment, she had three residual masses on CT scanning
ranging between 1 and 1.5cm. Relapse occurred 3 months after the
Table 1 Comparability of patient groups with and without residual lung lesions following chemotherapy for malignant GTN associated with lung
metastatses
All patients
No radiological abnormality after
chemotherapy
Radiologic abnormality
after chemotherapy
Number 76 53 23
Median age at presentation 31 years (range: 17–61) 31 years (range: 17–61) 32 years (range: 18–58)
Median follow-up 5 years (range: 1–9) 4 years (range: 1–9) 5 years (range: 1–9)
hCG at start of treatment 10900IUl
 1 (range 150–
2300000mmoll
 1)
110000IUl
 1 (range 150–
2300000mmoll
 1)
106000IUl
 1 (range 170–
1800000mmoll
 1)
Median duration of treatment 18 weeks (range 10–33) 18 weeks (range12–33) 16 weeks (range 10–29)
Proportion of high-risk patients (score48) 48 (63%) 33 (62%) 15 (65%)
Number of relapses 2 1 1
Table 2 Influence of CXR verses CT, size of lesion, number of lesions and type of malignant GTN on risk of having a persistent pulmonary lesion after
chemotherapy
Radiological investigation at completion of
chemotherapy
No radiological abnormality after
chemotherapy
Radiological abnormality after
chemotherapy
CXR 34 8
CT 19 15
w
2 P¼0.018
Size of largest lung metastasis at the beginning of treatment No radiological abnormality after chemotherapy Radiological abnormality after chemotherapy
o2cm 48 12
42cm 5 11
w
2 P¼0.001
Number of lung metastasis at the beginning of treatment No radiological abnormality after chemotherapy Radiological abnormality after chemotherapy
Less than 10 38 16
10 or more 15 7
w
2 P¼0.85
Type of GTN No radiological abnormality after chemotherapy Radiological abnormality after chemotherapy
Post molar malignant GTN (either invasive mole or
choriocarcinoma)
34 13
Known choriocarcinoma 19 10
w
2 P¼0.59
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scompletion of treatment with a rising hCG. She went on to receive
second line chemotherapy and eventually developed chemotherapy
resistant disease and died from progressive GTN. The second
patient had numerous 1–3cm lung metastasis and an hCG of
36000IUl
 1 at diagnosis. She received 17 weeks of combination
chemotherapy, which resulted in complete resolution of the lung
metastasis on CXR. The disease relapsed in multiple sites,
including the brain, 6 months later. She also eventually died from
her disease.
The 5-year disease-free outcome of the whole group was 97%
(95% CI: 3–100%). For those patients with and without a residual
abnormality, the 5-year disease-free survival was 95% (95% CI:
86–100%) and 98% (95% CI: 94–100%), respectively.
There was no significant difference in the disease-free outcome
of the patients with or without persistent radiological abnormality
(Figure 1).
DISCUSSION
Little is known about the outcome of patients with residual
pulmonary lesions, following successful chemotherapy for GTN
with lung metastases at diagnosis. Additionally, there is un-
certainty regarding the management of these residual lesions with
some advocating surgical removal (Ilancheran, 1998). However,
the work presented here shows that residual lung abnormalities in
women who are in marker remission following chemotherapy for
malignant GTN do not appear to have an increased risk of relapse.
Consequently, we believe that these lesions simply represent dead
tissue. Nevertheless, the absolute number of relapses in our study
was small, so we cannot exclude the possibility that there may be a
slight increased risk of relapse in patients with residual lung
lesions when a larger cohort of patients has been studied. So is
there any other data in the literature that might confirm or refute
our findings?
There have been several smaller studies investigating the role of
surgical resection for lung metastasis in GTN (Tomoda et al, 1980;
Saitoh et al, 1983; Xu et al, 1985; Jones et al, 1993). However,
unlike our study, all these have focused on surgery in patients with
an elevated hCG associated with chemoresistant tumours and
many were carried out before the introduction of curative
combination chemotherapy for high-risk disease. The most recent
of these studies was published in 1993 (Jones et al, 1993). Seven
patients had surgical resection after chemotherapy; none had a
normal serum hCG at the time of surgery. Additionally, five of the
patients had extra pulmonary metastasis known to be associated
with a poor prognosis. Indeed, three of these patients died of
extrapulmonary disease. Interestingly, two patients with isolated
pulmonary metastasis were cured by surgery as others have
previously reported (Sink et al, 1981). Thus, a thoracotomy in the
presence of a raised hCG is only likely to be helpful for isolated
chemoresistant lesions and not when there is widespread disease
(Sink et al, 1981). However, none of these studies really provides
any additional data to that presented here concerning the
management of residual lesions when the patients are in
biochemical complete remission with a normal hCG.
In our study, not all the patients had the same radiological
investigation at the end of treatment. Indeed, a higher proportion
of patients with radiological abnormality at the end of treatment
had CT scans. This is perhaps not surprising, as CT scanning is
more sensitive at identifying lung lesions than CXR. Nevertheless,
our results suggest that the observation of persistent radiological
abnormalities at the end of the treatment has no bearing on the
outcome for these patients. Therefore, the type of radiological test
performed may be irrelevant. In view of the radiation exposure
related to CT scanning, we do not recommend this investigation at
the end of the treatment in this young patient population.
Moreover, since radiological residual abnormalities in the chest
do not appear to predict subsequent disease course, and relapses
can be easily serologically detected by a rising hCG, one might be
tempted to advocate no chest imaging at this time. Nevertheless,
we still recommend performing a follow-up CXR on completion
of therapy for women with lung metastases at presentation. This
is because such imaging provides a useful baseline for future
comparison. For example, should the patient undergo chest
imaging for other reasons years later, the finding of a lung lesion
might not necessarily prompt additional investigation if compar-
ison with the previous films postchemotherapy shows no change.
In addition, should the patient relapse and a CXR demonstrate a
lung lesion, it would be important to know whether this was new,
enlarged from before, or old and unchanged.
Perhaps unsurprisingly, this study also shows that patients with
residual disease at the end of treatment have larger lung metastasis
at diagnosis (Table 2). It may be that larger pulmonary metastasis
result in more nonviable tissue after the completion of treatment.
In summary, chemotherapy alone cures the majority of patients
with isolated lung metastasis. Radiological abnormalities at the end
of treatment are of no prognostic significance if the patient is in
hCG remission, and excision of these lesions does not therefore
seem reasonable.
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